MedicineNews.net - Medical Updates

Opdivo plus Yervoy combined with two cycles of chemotherapy as first-line treatment of metastatic non-small cell lung cancer, positive CHMP opinion

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has recommended approval of Opdivo ( Nivolumab ) plus Yervoy ( Ipilimumab ) with two cycles of Plat ... read article

Lung cancer: patients with responsive to Nivolumab, an immunotherapic drug, beat standard odds of survival

More than seven years after the start of one of the first clinical trials of the immunotherapy drug Nivolumab ( Opdivo ), researchers at the Johns Hopkins Kimmel Cancer Center have reported that the f ... read article

TOWER trial: Blinatumomab met primary endpoint of overall survival in patients with B-cell precursor acute lymphoblastic leukemia

The results of a prespecified interim analysis have shown that the primary endpoint of improved overall survival was met in the phase 3 TOWER study. The randomized, open-label TOWER study evaluated ... read article

Pembrolizumab for the treatment of non-small cell lung carcinoma

Immune checkpoint inhibitors targeting programmed death protein 1 ( PD-1 ) receptor and its ligand, PD-L1, have recently led to significant and durable improvements in the clinical outcomes of some ty ... read article

Pan-cancer analysis of nearly 2,600 gynecologic and breast tumors has revealed five previously unknown subtypes

Researchers from The University of Texas MD Anderson Cancer Center have found a startling amount of new information about molecular features of tumors as well as identified previously unknown cancer s ... read article

Blinatumomab, a BITE antibody, has received FDA priority review designation in acute lymphoblastic leukemia

The FDA ( Food and Drug Administration ) has accepted for review the Biologics License Application ( BLA ) for the investigational bispecific T cell engager ( BiTE ) antibody construct, Blinatumomab. ... read article

MK-3475 shows encouraging results in treating non-small cell lung cancer

MK-3475, an experimental cancer drug, has shown early potential as an effective treatment for patients with non-small cell lung cancer ( NSCLC ).Preliminary results of a phase 1B study of MK-3475 were ... read article

Positive results of phase 3 Talimogene Laherparepvec trial in melanoma

Amgen has announced top-line results from the phase 3 trial in melanoma, which has evaluated the efficacy and safety of Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC or IV ... read article

Vedolizumab in the treatment of Crohn’s disease and ulcerative colitis

Biologic therapy for the treatment of inflammatory bowel disease ( IBD ) continues to evolve. Phase I and phase II studies have demonstrated the efficacy of Vedolizumab ( Entyvio ) for the induction o ... read article

Provenge, cellular immunotherapy for advanced prostate carcinoma

The FDA ( Food and Drug Administration ) has approved Provenge ( Sipuleucel-T ), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease. ... read article

Consolidation therapy following chemoimmunotherapy in B-cell chronic lymphocytic leukaemia: infection-related deaths reported with the use of MabCampath

Bayer HealthCare and Genzyme, in collaboration with Health Canada, informed of important safety information regarding the use of MabCampath ( Alemtuzumab ) as consolidation therapy following combinati ... read article

DNA of peanut-allergic children changes with immunotherapy

Treating a peanut allergy with oral immunotherapy changes the DNA of the patient's immune cells, according to a new study from the Stanford University School of Medicine and Lucile Packard Children's ... read article

Anti-TNF-alpha therapy provides relief for children newly diagnosed with Crohn's disease

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-alpha agents, according to a new study in Gastroenterology, the official journa ... read article